Article

CAMBRIDGE, Mass., Dec. 9, 2021 /PRNewswire/ -- Totus Medicines, a drug discovery company using breakthrough chemical biology to make the entire human genome druggable, today unveiled its revolutionary drug program targeting PI3Kα, the most commonly mutated cancer oncogene. The company also announced a $40 million Series A funding round led by investors DCVC Bio and Northpond Ventures and supported by Camford Capital with original seed funding from Social Impact Capital. The Series A financing will be used to expand and scale Totus Medicines' proprietary drug discovery platform and advance the company's lead program into the clinic.